WO2013161676A1 - コレステロールオキシダーゼの安定化方法 - Google Patents
コレステロールオキシダーゼの安定化方法 Download PDFInfo
- Publication number
- WO2013161676A1 WO2013161676A1 PCT/JP2013/061529 JP2013061529W WO2013161676A1 WO 2013161676 A1 WO2013161676 A1 WO 2013161676A1 JP 2013061529 W JP2013061529 W JP 2013061529W WO 2013161676 A1 WO2013161676 A1 WO 2013161676A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholesterol oxidase
- acid
- sample
- cholesterol
- keto acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03006—Cholesterol oxidase (1.1.3.6)
Definitions
- the present invention relates to a method for stabilizing cholesterol oxidase, a method for storing cholesterol oxidase, and a composition for stabilizing cholesterol oxidase.
- Cholesterol oxidase is an oxidoreductase that uses cholesterol and oxygen molecules as substrates. In clinical tests, cholesterol is often measured using cholesterol oxidase. Cholesterol oxidase acts on cholesterol in the sample to produce hydrogen peroxide. The resulting hydrogen peroxide reacts with oxidative coloring chromogen in the presence of peroxidase to lead to the dye, and the absorbance of the dye is measured. A method for measuring cholesterol in a specimen by a colorimetric method, etc., is used in clinical tests.
- JP-A-52-143285 JP-A-6-062846 Japanese Patent Laid-Open No. 8-187095 JP 2005-114368 A
- An object of the present invention is to provide a method for stabilizing cholesterol oxidase suitable for long-term storage, a method for storing cholesterol oxidase, and a composition for stabilizing cholesterol oxidase.
- the present inventors have found that cholesterol oxidase is stably maintained by coexisting cholesterol oxidase with ⁇ -keto acid or a salt thereof in an aqueous medium.
- the headline and the present invention were completed. That is, the present invention relates to the following [1] to [6].
- ⁇ -keto acid is ⁇ -keto acid selected from the group consisting of pyruvic acid, ⁇ -ketoglutaric acid and oxaloacetic acid.
- the ⁇ -keto acid is ⁇ -keto acid selected from the group consisting of pyruvic acid, ⁇ -ketoglutaric acid and oxaloacetic acid.
- the ⁇ -keto acid is ⁇ -keto acid selected from the group consisting of pyruvic acid, ⁇ -ketoglutaric acid and oxaloacetic acid.
- the present invention provides a method for stabilizing cholesterol oxidase, a method for storing cholesterol oxidase, and a composition for stabilizing cholesterol oxidase suitable for long-term storage.
- the method for stabilizing cholesterol oxidase according to the present invention is characterized in that ⁇ -keto acid or a salt thereof coexists in cholesterol oxidase in an aqueous medium.
- the method for preserving cholesterol oxidase according to the present invention is a method characterized in that ⁇ -keto acid or a salt thereof coexists in cholesterol oxidase in an aqueous medium.
- the stabilized composition of cholesterol oxidase of the present invention is a composition characterized in that ⁇ -keto acid or a salt thereof coexists in cholesterol oxidase in an aqueous medium.
- “stable” means that the enzyme activity of cholesterol oxidase is maintained even when cholesterol oxidase is stored for a long period of time. Specifically, an aqueous solution of cholesterol oxidase is stored at 5 ° C. for 2 weeks. The cholesterol oxidase activity after storage at 5 ° C. for 2 weeks is 75% or more of the cholesterol oxidase activity immediately after the preparation of the cholesterol oxidase aqueous solution. Cholesterol oxidase activity can be measured, for example, by the following method.
- a cholesterol oxidase activity evaluation reagent containing cholesterol and a detection reagent is prepared.
- a detection reagent for example, a reagent containing peroxidase and an oxidative coloring chromogen described later can be used.
- a reagent for evaluating cholesterol oxidase activity (y ⁇ L) is added to sample A (x ⁇ L), reacted at 37 ° C. for 5 minutes, and the absorbance E1 A of the reaction solution after 5 minutes of reaction is measured. Further subjected to reaction for 5 minutes at 37 ° C., absorbance E2 A of the reaction solution after the reaction 10 minutes was measured to calculate the E2 absorbance difference obtained by subtracting the E1 A from A Delta] E 'A.
- cholesterol oxidase activity is proportional to Delta] E A, as an index of cholesterol oxidase activity, can be used Delta] E A.
- the stabilization of cholesterol oxidase can be evaluated by, for example, the following method.
- sample A for sample A prepared by adding cholesterol oxidase and ⁇ -keto acid to the buffer, sample A (immediately after preparation) and sample A (immediately after preparation) are stored at 5 ° C for 2 weeks.
- sample A for sample a without ⁇ -keto acid prepared by adding only cholesterol oxidase to the buffer, sample a (immediately after preparation) and sample a (immediately after preparation) were stored at 5 ° C. for 2 weeks.
- Prepare a later specimen a (after storage) for sample containing cholesterol oxidase
- sample A prepared by adding cholesterol oxidase and ⁇ -keto acid to the buffer
- sample A immediately after preparation
- sample A for sample A without ⁇ -keto acid prepared by adding only cholesterol oxidase to the buffer
- sample a (immediately after preparation) and sample a were stored at 5 ° C. for 2 weeks.
- sample A (immediately after preparation) as a sample
- the reaction between sample A (immediately after preparation) and the cholesterol oxidase activity evaluation reagent is performed at 37 ° C. for 5 minutes, and the absorbance E1 A (immediately after preparation) of the reaction solution is measured. Further, the reaction was carried out at 37 ° C for 5 minutes, and the absorbance E2 A (immediately after preparation) of the reaction solution 10 minutes after the reaction was measured, and the difference in absorbance ⁇ E ' A obtained by subtracting E1 A (immediately after preparation ) from E2 A (immediately after preparation). Calculate (immediately after preparation) .
- the absorbance E1 0 of the reaction solution after 5 minutes of reaction at 37 ° C. were measured, for 5 minutes reaction was further 37 ° C.
- the absorbance E2 O of the reaction solution after the reaction 10 minutes was measured to calculate the absorbance difference Delta] E O minus the E1 O from E2 O.
- ⁇ E O is subtracted from ⁇ E ′ A (immediately after preparation) to obtain an absorbance difference ⁇ E A (immediately after preparation) with respect to specimen A (immediately after preparation) .
- the absorbance difference ⁇ E A (after storage) with respect to the sample A (after storage) is calculated by the same method as described above except that the sample A (after storage) is used instead of the sample A ( immediately after preparation) .
- the specimen A (immediately after preparation) calculating the analyte a absorbance difference Delta] E a for (after storage) (after storage) by using a sample a (after storage) instead of.
- the residual rate of cholesterol oxidase in the sample A is calculated by the following formula (II).
- Cholesterol oxidase in the present invention is an enzyme classified into EC 1.1.3.6 and an enzyme that catalyzes the following reaction. Cholesterol + O 2 ⁇ Cholest-4-en-one + H 2 O 2
- cholesterol oxidase examples include cholesterol oxidase produced by genetic engineering techniques, in addition to cholesterol oxidase derived from animals, plants or microorganisms.
- Cholesterol oxidase (CHODI; manufactured by Kikkoman)
- cholesterol Commercial products such as oxidase (CHO-PEWL; manufactured by Kikkoman Corp.), cholesterol oxidase (CHO-CE; manufactured by Kikkoman Corp.), cholesterol oxidase (COO-321; manufactured by Toyobo Co., Ltd.) and the like can also be used.
- the aqueous medium is not particularly limited as long as it is an aqueous medium that can stably hold cholesterol oxidase.
- examples thereof include deionized water, distilled water, and a buffer solution, and a buffer solution is preferable.
- the concentration of cholesterol oxidase in the aqueous medium in the present invention is usually 0.01 to 300 U / mL.
- a buffering agent having a buffering ability in a pH region capable of stably holding cholesterol oxidase is preferable, and examples thereof include a phosphate buffer solution, a borate buffer solution, and a Good buffer solution.
- Examples of the Good buffer used in the Good buffer include 2-morpholinoethanesulfonic acid (MES), tris (hydroxymethyl) aminomethane (Tris), bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane (Bis -Tris), N- (2-acetamido) iminodiacetic acid (ADA), piperazine-N, N'-bis (2-ethanesulfonic acid) (PIPES), N- (2-acetamido) -2-aminoethanesulfone Acid (ACES), N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic acid (BES), 3-morpholinopropanesulfonic acid (MOPS), N- [tris (hydroxymethyl) methyl] -2- Aminoethanesulfonic acid (TES), 2- [4- (2-hydroxyethyl) -1-piperazinyl] ethanesulfonic acid (HEPES), piperaz
- the ⁇ -keto acid in the present invention is not particularly limited as long as it is an ⁇ -keto acid that stabilizes cholesterol oxidase, and examples thereof include pyruvic acid, ⁇ -ketoglutaric acid, and oxaloacetic acid.
- ⁇ -keto acid may be a salt, and examples of the salt include lithium salt, sodium salt, potassium salt, ammonium salt, calcium salt, magnesium salt and the like.
- the concentration of ⁇ -keto acid in the aqueous medium in the present invention is not particularly limited as long as it is a concentration that stabilizes cholesterol oxidase, and is usually 0.05 to 40 mmol / L.
- the method for preserving cholesterol oxidase of the present invention is a method for preserving cholesterol oxidase in the presence of ⁇ -keto acid or a salt thereof in an aqueous medium.
- the cholesterol oxidase and its concentration, and the ⁇ -keto acid and its concentration used in the method for preserving cholesterol oxidase of the present invention are the same as those in the above-mentioned cholesterol oxidase stabilization method.
- the storage period in the method for storing cholesterol oxidase of the present invention is not particularly limited as long as cholesterol oxidase is stably stored, and is usually 1 to 2 years.
- the storage temperature in the method for storing cholesterol oxidase of the present invention is not particularly limited as long as it is a temperature at which cholesterol oxidase is stably stored, and is usually -5 to 45 ° C, preferably 0 to 30 ° C, 2 ⁇ 10 ° C. is particularly preferred.
- a surfactant, preservative, protein, and the like may coexist in cholesterol oxidase.
- the surfactant include nonionic surfactants, cationic surfactants, anionic surfactants, and amphoteric surfactants.
- preservatives include azides and chelating agents. Examples of the azide include sodium azide. Examples of the chelating agent include ethylenediaminetetraacetic acid (EDTA) or a salt thereof. Examples of the salt include sodium salt and potassium salt.
- the protein include albumin and the like, and examples of albumin include bovine serum albumin (BSA) and the like.
- the stabilized composition of cholesterol oxidase of the present invention is usually included in reagents and kits used in the measurement method of the measurement target component based on the hydrogen peroxide measurement system. May be included.
- Components to be measured include total cholesterol (TC), cholesterol in high density lipoprotein (HDL-C), cholesterol in intermediate density lipoprotein (IDL-C), cholesterol in low density lipoprotein (LDL-C) , Cholesterol in very low density lipoprotein (VLDL-C), cholesterol in remnant-like lipoprotein (RLP-C), cholesterol in small particle low density lipoprotein (sdLDL-C), cholesterol in HDL subfractions (HDL2-C, HDL3-C), free cholesterol (FC) and the like.
- TC total cholesterol
- HDL-C high density lipoprotein
- IDL-C intermediate density lipoprotein
- LDL-C low density lipoprotein
- RVLP-C cholesterol in remnant-like lipoprotein
- sdLDL-C cholesterol in HDL subfractions
- HDL2-C, HDL3-C free cholesterol
- reagents and kits used for measuring cholesterol (TC, HDL-C, LDL-C, IDL-C, VLDL-C, RLP-C, sdLDL-C, HDL2-C, HDL3-C, FC)
- cholesterol oxidase cholesterol esterase, peroxidase, oxidative coloring type chromogen and the like are contained.
- Examples of the oxidative coloring type chromogen include a leuco chromogen and an oxidative coupling chromogen.
- the leuco chromogen has a function of reacting with hydrogen peroxide in the presence of peroxidase to generate a dye alone.
- leuco chromogens include tetramethylbenzidine, o-phenylenediamine, 10-N-carboxymethylcarbamoyl-3,7-bis (dimethylamino) -10H-phenothiazine (CCAP), 10-N-methylcarbamoyl- 3,7-bis (dimethylamino) -10H-phenothiazine (MCDP), N- (carboxymethylaminocarbonyl) -4,4'-bis (dimethylamino) diphenylamine sodium salt (DA-64), 10-N- ( Carboxymethylaminocarbonyl) -3,7-bis (dimethylamino) -10H-phenothiazine sodium salt (DA-67), 4,4'-bis (dimethylamino) diphenylamine, bis [3-bis (4
- the oxidative coupling chromogen has a function of reacting with hydrogen peroxide in the presence of peroxidase to produce a dye.
- a combination of a pair of oxidative coupling chromogens is used.
- Examples of the combination of a pair of oxidative coupling chromogens include a combination of a coupler and an aniline, and a combination of a coupler and a phenol.
- coupler examples include 4-aminoantipyrine (4-AA) and 3-methyl-2-benzothiazolinone hydrazine.
- anilines include N- (3-sulfopropyl) aniline, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -3-methylaniline (TOOS), N-ethyl-N- (2-hydroxy -3-sulfopropyl) -3,5-dimethylaniline (MAOS), N-ethyl-N- (2-hydroxy-3-sulfopropyl) -3,5-dimethoxyaniline (DAOS), N-ethyl-N- (3-sulfopropyl) -3-methylaniline (TOPS), N- (2-hydroxy-3-sulfopropyl) -3,5-dimethoxyaniline (HDAOS), N, N-dimethyl-3-methylaniline, N , N-di (3-sulfopropyl) -3,5-dimethoxyaniline, N-ethyl-N- (3-sulfopropyl) -3-methoxyaniline (
- phenols examples include phenol, 4-chlorophenol, 3-methylphenol, 3-hydroxy-2,4,6-triiodobenzoic acid (HTIB) and the like.
- the stabilized composition of cholesterol oxidase of the present invention may contain the aforementioned surfactant, preservative, protein and the like.
- Reagent for measuring cholesterol oxidase activity Reagent A and reagent B having the following composition were prepared.
- cholesterol is used regardless of whether a sample (A0 to A3) containing no surfactant is used or a sample (B0 to B3) containing a surfactant.
- the residual rate of oxidase was higher in the presence of ⁇ -keto acid than in the absence of ⁇ -keto acid, and was found to be 75% or more.
- the residual rate was as low as less than 75%. Accordingly, it was found that cholesterol oxidase is stabilized by allowing ⁇ -keto acid or a salt thereof to coexist in cholesterol oxidase in an aqueous medium.
- the present invention provides a method for stabilizing cholesterol oxidase, a method for storing cholesterol oxidase, and a composition for stabilizing cholesterol oxidase.
- the method for stabilizing cholesterol oxidase, the method for preserving cholesterol oxidase, and the composition for stabilizing cholesterol oxidase of the present invention are useful for clinical diagnosis of metabolic syndrome and the like.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
この課題に対して、コレステロールオキシダーゼを含む溶液にアルカリ金属の塩化物および/またはアルカリ土類金属の塩化物を添加するコレステロールオキシダーゼの安定化方法(特許文献1参照)、ウシ血清アルブミン、デキストラン、ポリエチレングリコールから選択される水溶性担体と化学結合させることによる、溶液状態におけるコレステロールオキシダーゼの安定化方法(特許文献2参照)、コレステロールオキシダーゼを含む溶液に、牛血清アルブミン及びリジンを添加することによりコレステロールオキシダーゼを安定化する方法(特許文献3参照)、タンパク質分解物と共存させることによる乾燥状態のコレステロールオキシダーゼを安定化する方法(特許文献4参照)等が知られている。
[1] コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とするコレステロールオキシダーゼの安定化方法。
[2] α-ケト酸が、ピルビン酸、α-ケトグルタル酸及びオキサロ酢酸からなる群より選ばれるα-ケト酸である[1]記載の安定化方法。
[3] コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とするコレステロールオキシダーゼの保存方法。
[4] α-ケト酸が、ピルビン酸、α-ケトグルタル酸及びオキサロ酢酸からなる群より選ばれるα-ケト酸である[3]記載の保存方法。
[5] コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とするコレステロールオキシダーゼの安定化組成物。
[6] α-ケト酸が、ピルビン酸、α-ケトグルタル酸及びオキサロ酢酸からなる群より選ばれるα-ケト酸である[5]記載の安定化組成物。
本発明のコレステロールオキシダーゼの保存方法は、コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とする方法である。
本発明のコレステロールオキシダーゼの安定化組成物は、コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とする組成物である。
コレステロール+O2→ コレスト-4-エン-オン+H2O2
本発明において、コレステロールオキシダーゼは、通常、pH5~9の水性媒体中で保存され、pH6~8の水性媒体中で保存されることが好ましい。
MOPS(同仁化学研究所社製)、EMSE(ダイトーケミックス社製)、4-AA(アクテック社製)、バイオエース(ケイ・アイ化成社製)、PGM-50(ポリオキシエチレンオクチルフェニルエーテル;和光純薬工業社製)、コール酸ナトリウム(ナカライテスク社製)、コレステロール(純正化学社製)、2-プロパノール(和光純薬工業社製)、トリトンX-100(シグマ社製)、ピルビン酸ナトリウム(関東化学社製)、α-ケトグルタル酸・2ナトリウム(MPバイオメディカル社製)、オキサロ酢酸(関東化学社製)、ペルオキシダーゼ(東洋紡績社製)、CHO-CE(コレステロールオキシダーゼ;キッコーマン社製)。
(1)検体
以下の組成からなる検体A(検体A0~A3)、及び、検体B(検体B0~B3)を調製した。
<検体A(検体A0~A3)>
MOPS(pH7.0) 20 mmol/L
CHO-CE 2 kU/L
α-ケト酸(第1表参照、検体A0は無添加)
<検体B(検体B0~B3)>
MOPS(pH7.0) 20 mmol/L
トリトンX-100 1%
CHO-CE 2 kU/L
α-ケト酸(第1表参照、検体B0は無添加)
以下の組成からなる試薬A、及び、試薬Bを調製した。
<試薬A>
MOPS(pH7.0) 50 mmol/L
EMSE 0.3 g/L
4-AA 0.1 g/L
バイオエース 0.3 g/L
PGM-50 10 g/L
コール酸ナトリウム 5 g/L
ペルオキシダーゼ 15 kU/L
<試薬B>
コレステロールの2-プロパノール溶液(5 mg/mL)
試薬A(50 mL)に試薬B(2 mL)添加し、よく攪拌し、コレステロールオキシダーゼ活性測定用試薬とした。
反応セルへ調製直後の検体A1(2.4μL)と、上記(2)のコレステロールオキシダーゼ活性測定用試薬(225μL)とを添加し、37℃で5分間加温した後の反応液の吸光度E1A1(調製直後)を主波長546 nm、副波長800 nmで測定し、さらに37℃で5分間加温し、反応10分後の反応液の吸光度E2A1(調製直後)を主波長546 nm、副波長800 nmで測定し、E2A1(調製直後)からE1A1(調製直後)を差し引き、ΔE’A1(調製直後)とした。
調製直後の検体A1の代わりに、5℃2週間保存後の検体A1を用いる以外は上記(3)と同様の方法により、5℃2週間保存後の検体A1に対する吸光度差ΔEA1(保存後)を決定した。
上記(3)で決定したΔEA1(調製直後)と(4)で決定したΔEA1(保存後)とから、調製直後の検体中のコレステロールオキシダーゼに対する5℃2週間保存後の検体中のコレステロールオキシダーゼの残存率を上記式(II)により決定した。結果を第1表に示す。
さらに、検体A1の代わりに、検体A0及び検体B0を用い、上記式(II)の代わりに、上記式(III)を用いる以外は上記(1)~(5)と同様の方法により、調製直後の各検体中のコレステロールオキシダーゼに対する、5℃2週間保存後の各検体中のコレステロールオキシダーゼの残存率を決定した。結果を第1表に示す。
Claims (6)
- コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とするコレステロールオキシダーゼの安定化方法。
- α-ケト酸が、ピルビン酸、α-ケトグルタル酸及びオキサロ酢酸からなる群より選ばれるα-ケト酸である請求項1記載の安定化方法。
- コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とするコレステロールオキシダーゼの保存方法。
- α-ケト酸が、ピルビン酸、α-ケトグルタル酸及びオキサロ酢酸からなる群より選ばれるα-ケト酸である請求項3記載の保存方法。
- コレステロールオキシダーゼにα-ケト酸若しくはその塩を水性媒体中で共存させることを特徴とするコレステロールオキシダーゼの安定化組成物。
- α-ケト酸が、ピルビン酸、α-ケトグルタル酸及びオキサロ酢酸からなる群より選ばれるα-ケト酸である請求項5記載の安定化組成物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13780836.6A EP2843045B1 (en) | 2012-04-27 | 2013-04-18 | Method for stabilizing cholesterol oxidase |
CA2869445A CA2869445C (en) | 2012-04-27 | 2013-04-18 | Method for stabilizing cholesterol oxidase |
CN201380021290.1A CN104245931B (zh) | 2012-04-27 | 2013-04-18 | 胆固醇氧化酶的稳定化方法 |
KR1020147028791A KR101972628B1 (ko) | 2012-04-27 | 2013-04-18 | 콜레스테롤옥시다아제의 안정화 방법 |
BR112014025874-0A BR112014025874B1 (pt) | 2012-04-27 | 2013-04-18 | métodos para estabilizar uma colesterol oxidase e para preservar uma colesterol oxidase |
JP2014512509A JP6124414B2 (ja) | 2012-04-27 | 2013-04-18 | コレステロールオキシダーゼの安定化方法 |
US14/391,512 US9683228B2 (en) | 2012-04-27 | 2013-04-18 | Method for stabilizing cholesterol oxidase |
HK15103495.7A HK1202895A1 (en) | 2012-04-27 | 2015-04-09 | Method for stabilizing cholesterol oxidase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012103257 | 2012-04-27 | ||
JP2012-103257 | 2012-04-27 | ||
JP2012-119583 | 2012-05-25 | ||
JP2012119583 | 2012-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013161676A1 true WO2013161676A1 (ja) | 2013-10-31 |
Family
ID=49482997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/061529 WO2013161676A1 (ja) | 2012-04-27 | 2013-04-18 | コレステロールオキシダーゼの安定化方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9683228B2 (ja) |
EP (1) | EP2843045B1 (ja) |
JP (1) | JP6124414B2 (ja) |
KR (1) | KR101972628B1 (ja) |
CN (1) | CN104245931B (ja) |
BR (1) | BR112014025874B1 (ja) |
CA (1) | CA2869445C (ja) |
HK (1) | HK1202895A1 (ja) |
WO (1) | WO2013161676A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021040516A (ja) * | 2019-09-10 | 2021-03-18 | デンカ生研株式会社 | キットおよび方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106520717A (zh) * | 2016-12-14 | 2017-03-22 | 曹书华 | 一种提高胆固醇氧化酶对底物谷甾醇的特异性的方法 |
US11808727B2 (en) * | 2017-07-06 | 2023-11-07 | Polymer Technology Systems, Inc. | Systems and methods for an electrochemical total cholesterol test |
KR102200726B1 (ko) | 2019-09-27 | 2021-01-08 | 주식회사 포스코 | 플랜트의 전력 관리 장치 및 방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52143285A (en) | 1976-05-26 | 1977-11-29 | Kikkoman Corp | Stabilization of cholesterol-oxydase |
JPH0662846A (ja) | 1992-08-12 | 1994-03-08 | Eiken Chem Co Ltd | 分析試薬用酵素の安定化法、および溶液状の分析試薬用酵素 |
JPH08187095A (ja) | 1995-01-10 | 1996-07-23 | Toyobo Co Ltd | コレステロールオキシダーゼの安定化法 |
JP2002233363A (ja) * | 2001-02-08 | 2002-08-20 | Unitika Ltd | アスコルビン酸オキシダーゼの安定化方法および生体成分測定用試薬 |
JP2005114368A (ja) | 2003-10-02 | 2005-04-28 | Arkray Inc | 酵素の安定化方法およびそれに用いる検体分析用具 |
JP2010172346A (ja) * | 1999-06-21 | 2010-08-12 | Sekisui Medical Co Ltd | コレステロール定量用試料の前処理方法およびこれを利用する特定のリポ蛋白中のコレステロール定量法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2755799B1 (de) | 1977-12-14 | 1978-08-03 | Boehringer Mannheim Gmbh | Lagerfaehige Cholesterinoxidasepraeparation |
JPS5886083A (ja) | 1981-11-12 | 1983-05-23 | Wako Pure Chem Ind Ltd | グリセロ−ル−3−リン酸オキシダ−ゼの安定化剤 |
US5047327A (en) * | 1982-04-02 | 1991-09-10 | Ivan E. Modrovich | Time-stable liquid cholesterol assay compositions |
-
2013
- 2013-04-18 CA CA2869445A patent/CA2869445C/en active Active
- 2013-04-18 KR KR1020147028791A patent/KR101972628B1/ko active IP Right Grant
- 2013-04-18 EP EP13780836.6A patent/EP2843045B1/en active Active
- 2013-04-18 CN CN201380021290.1A patent/CN104245931B/zh active Active
- 2013-04-18 US US14/391,512 patent/US9683228B2/en active Active
- 2013-04-18 JP JP2014512509A patent/JP6124414B2/ja active Active
- 2013-04-18 WO PCT/JP2013/061529 patent/WO2013161676A1/ja active Application Filing
- 2013-04-18 BR BR112014025874-0A patent/BR112014025874B1/pt active IP Right Grant
-
2015
- 2015-04-09 HK HK15103495.7A patent/HK1202895A1/xx unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52143285A (en) | 1976-05-26 | 1977-11-29 | Kikkoman Corp | Stabilization of cholesterol-oxydase |
JPH0662846A (ja) | 1992-08-12 | 1994-03-08 | Eiken Chem Co Ltd | 分析試薬用酵素の安定化法、および溶液状の分析試薬用酵素 |
JPH08187095A (ja) | 1995-01-10 | 1996-07-23 | Toyobo Co Ltd | コレステロールオキシダーゼの安定化法 |
JP2010172346A (ja) * | 1999-06-21 | 2010-08-12 | Sekisui Medical Co Ltd | コレステロール定量用試料の前処理方法およびこれを利用する特定のリポ蛋白中のコレステロール定量法 |
JP2002233363A (ja) * | 2001-02-08 | 2002-08-20 | Unitika Ltd | アスコルビン酸オキシダーゼの安定化方法および生体成分測定用試薬 |
JP2005114368A (ja) | 2003-10-02 | 2005-04-28 | Arkray Inc | 酵素の安定化方法およびそれに用いる検体分析用具 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021040516A (ja) * | 2019-09-10 | 2021-03-18 | デンカ生研株式会社 | キットおよび方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2869445C (en) | 2020-05-05 |
CN104245931A (zh) | 2014-12-24 |
EP2843045A1 (en) | 2015-03-04 |
HK1202895A1 (en) | 2015-10-09 |
EP2843045A4 (en) | 2015-11-04 |
CA2869445A1 (en) | 2013-10-31 |
KR101972628B1 (ko) | 2019-04-25 |
CN104245931B (zh) | 2017-06-09 |
BR112014025874B1 (pt) | 2021-05-25 |
KR20150013452A (ko) | 2015-02-05 |
EP2843045B1 (en) | 2017-10-18 |
JP6124414B2 (ja) | 2017-05-10 |
US9683228B2 (en) | 2017-06-20 |
JPWO2013161676A1 (ja) | 2015-12-24 |
US20150104847A1 (en) | 2015-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2843054B1 (en) | Method for measuring component to be measured in specimen | |
JP6124414B2 (ja) | コレステロールオキシダーゼの安定化方法 | |
JP6004942B2 (ja) | 測定対象成分の測定方法 | |
JP6132837B2 (ja) | アスコルビン酸オキシダーゼの安定化方法 | |
EP2740801B1 (en) | Sphingomyelin measurement method and measurement kit | |
JP2005110507A (ja) | 試薬の安定化方法 | |
WO2012124340A1 (ja) | Hdl亜分画中のコレステロールの測定方法、測定用試薬及び測定用キット | |
WO2014034822A1 (ja) | カタラーゼの安定化方法 | |
JP2021007389A (ja) | 安定化剤を含有する糖化タンパク質測定試薬用の4−アミノアンチピリン含有部分組成物、糖化タンパク質測定試薬、糖化タンパク質の測定方法、糖化タンパク質測定試薬用の4−アミノアンチピリン含有部分組成物の安定化方法、及び糖化タンパク質測定試薬用の4−アミノアンチピリン含有部分組成物の保存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13780836 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014512509 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2869445 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14391512 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20147028791 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013780836 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013780836 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014025874 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014025874 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141016 |